TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05105126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC).~The cathode electrode will be placed on the right dorsolateral prefrontal cortex.~40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC).~The cathode electrode will be placed on the right dorsolateral prefrontal cortex.~40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS
Study: NCT04652284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40 mg
Study: NCT06619821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
Study: NCT04652284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: 500 mg
Study: NCT06411340

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT05943119

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy in painting dose on histoscannographic mapping
Description: The target volumes to be delineated are as follows:~* High-risk CTV (Clinical Target Volume), corresponding to all initially invaded areas, as identified by comparison between the operative report and the anatomo-pathological report (ideally with histo-surgical mapping).~* Low-risk CTV, corresponding to naso-sinusal structures not initially invaded but at risk of recurrence, and located close to the high-risk target volume, including at least 5 mm around the high-risk volume and excluding non-risk areas (muscle, bone).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard pan-sinusal Radiotherapy
Description: The target volumes to be delineated are as follows:~* High-risk CTV, including the entire post-operative cavity,~* Low-risk CTV, adapted from the recommendations described by Lapeyre (Cancer/Radiotherapy 2005), and including at least 5 mm around the high-risk volume, excluding non-risk areas (muscle, bone).
Study: NCT06619821

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
Study: NCT06619899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAP exercise with 0% body mass
Description: The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAP exercise with 20% body mass
Description: Description: The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No PAP exercise
Description: No PAP exercise will be performed. The participants will perform only 6 x 30m sprints.
Study: NCT06691126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Terpinolene in olive oil
Description: Single oral dose of 200mg food-grade terpinolene in 5ml of olive oil
Study: NCT06712602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol
Description: During the alcohol administration session participants will receive a single administration of alcohol (0.5 g/kg) mixed with lemon lime soda. Participants will consume the drink within 5 min.
Study: NCT04962477

Intervention type: OTHER
Intervention: Nasal brush sampling
Description: Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.

Intervention type: OTHER
Intervention: Nasal brush sampling
Description: Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.
Study: NCT04504708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
Study: NCT06712602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol
Description: During the alcohol administration session participants will receive a single administration of alcohol (0.5 g/kg) mixed with lemon lime soda. Participants will consume the drink within 5 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-Induction
Description: The stress-induction procedure is the Cold Pressure Test \[CPT\]) stressor. The bilateral foot CPT requires participants to submerge both feet in ice-cold water (24°C) for 3 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-Induction
Description: The stress-induction procedure is the Cold Pressure Test \[CPT\]) stressor. The bilateral foot CPT requires participants to submerge both feet in ice-cold water (24°C) for 3 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT150
Description: Participants will ingest PT150 (0, 225, 450 mg) twice daily (e.g., 0800, 2000h) for 5 five days prior to the conduct of the experimental sessions. The sequence of PT150 doses will be quasi-random such that participants will be maintained on the lower dose of PT150 (i.e., 225 mg twice/day) before the higher dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT150
Description: Participants will ingest PT150 (0, 225, 450 mg) twice daily (e.g., 0800, 2000h) for 5 five days prior to the conduct of the experimental sessions. The sequence of PT150 doses will be quasi-random such that participants will be maintained on the lower dose of PT150 (i.e., 225 mg twice/day) before the higher dose.
Study: NCT06715345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone graft materials and rhBMP-2
Description: NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone graft materials and rhBMP-2
Description: NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone graft materials and rhBMP-2
Description: NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.
Study: NCT06716164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
Study: NCT06708338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle bevel orientation for arteriovenous fistula puncture
Description: For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.~Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:~* Bevel-up group~* Bevel-down group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle bevel orientation for arteriovenous fistula puncture
Description: For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.~Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:~* Bevel-up group~* Bevel-down group
Study: NCT06718738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM96 CAR-T Cells
Description: IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
Study: NCT06718231

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical acupoint stimulation
Description: After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints, and sham acupoints. The target treatment acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham-TAES
Description: After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral sham acupoints. The Sham acupoints is 4 cm interior to the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints. The sham acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery
Study: NCT05833906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 1
Description: Subjects will be administered 5 g of CKR-051.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 2
Description: Subjects will be administered 10 g of CKR-051.
Study: NCT03662633

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast cancer group
Description: All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Benign breast tumor group
Description: All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
Study: NCT05833906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 2
Description: Subjects will be administered 10 g of CKR-051.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 3
Description: Subjects will be administered 10 g of CKR-051.
Study: NCT06716242

Intervention type: PROCEDURE
Intervention: Peripheral blood collection
Description: Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.
Study: NCT05833906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 3
Description: Subjects will be administered 10 g of CKR-051.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 4
Description: Subjects will be administered 10 g of CKR-051.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKR-051 Dose 4
Description: Subjects will be administered 10 g of CKR-051.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator.
Study: NCT06075472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training (IMT) is a therapeutic technique which involves specific training of respiratory muscles to yield improvements in inspiratory muscle strength and respiratory function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Exercises
Description: Balance exercises involve functional movements at the individual's maximum level of independence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Exercises
Description: Balance exercises involve functional movements at the individual's maximum level of independence.
Study: NCT06716931

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A patient-friendly exercise routine has been designed for patients with myotonic dystrophy type 2. Benefits of this exercise regimen in different settings (at home versus clinic, self-directed versus physical therapist-directed) will be investigated.~In person exercise supervised by physical therapist and then self-directed exercise in Group A

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise virtually supervised by physical therapist and then self-directed for group B

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Self-directed and virtually supervised exercise by physical therapist for Group C
Study: NCT06714708

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Radiation: 30Gy/15F Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
Study: NCT06717880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 combined with Bevacizumab
Description: IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection.~Bevacizumab, intravenous injection.
Study: NCT06717568

Intervention type: DIAGNOSTIC_TEST
Intervention: no intervention
Description: This is a diagnostic test with no intervention.
Study: NCT05173038

Intervention type: BEHAVIORAL
Intervention: second ejaculate
Description: group patients received IUI for pregnancy assistance 1 hour after the first sperm extraction. The two semen were mixed and treated.
Study: NCT04414436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GYNEA- digital coping program for women after gynaecological cancer
Description: 6 modules with relevant information and tools for coping after cancer
Study: NCT06206083

Intervention type: GENETIC
Intervention: Descriptive and analytical
Description: Patients with EC endometroid
Study: NCT06719440

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy as SoC for glioblastoma

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy as SoC for glioblastoma
Study: NCT05536830

Intervention type: OTHER
Intervention: Nutrition Status
Description: Participants will be examined by a registered dietitian to assess nutrition status.
Study: NCT06719102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAGIC-FEED
Description: Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that includes bottle-/breast-feeding and complementary feeding in alignment with the Dietary Guidelines. The intervention is delivered via virtual visits, binder, website and newsletters.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MAGIC-SAFE
Description: Parents will be provided with information about age-appropriate safety topics, including safe sleeping, car seats, baby-proofing, etc. The intervention is delivered via virtual visits, binder, website and newsletters.
Study: NCT04641390

Intervention type: OTHER
Intervention: Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment
Description: The analysis of the seminal microbiome will be carried out by massive genetic sequencing

Intervention type: OTHER
Intervention: Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment
Description: The analysis of the seminal microbiome will be carried out by massive genetic sequencing
Study: NCT06436729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Splinting
Description: The joining of two or more teeth into a rigid unit by means of a fixed or removable restorations/devices

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MINST alone
Description: Minimally invasive non surgical therapy alone
Study: NCT04755465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise
Description: Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise
Description: Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
Study: NCT05087459

Intervention type: DRUG
Intervention: Avatrombopag
Description: On the basis of conventional treatment, Avatrombopag was added, 30×10\^9/L \< platelet count \< 50×10\^9/L patients received Avatrombopag 60mg/d, 50×10\^9/L≤ platelet count \< 75×10\^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.